GlassScriptPhysician profile
Kyle L Caulfield
NPI 1164420162
$6,128.17
in general payments reported to CMS, 2019-2025
54 companies · $654 in 2025
The $654 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $891 · 2021: $1,456 · 2022: $875 · 2023: $693 · 2024: $543 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $857.22 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $470.78 | 2019-2024 | Trelegy Ellipta |
| Abbvie INC. | $350.30 | 2019-2024 | Ubrelvy |
| Amarin Pharma, INC. | $322.62 | 2019-2022 | |
| Pfizer INC. | $317.32 | 2019-2025 | |
| Amgen INC. | $296.71 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.26 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $279.71 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $218.97 | 2020-2022 | |
| Abbott Laboratories | $187.88 | 2021-2022 | |
| Novo Nordisk INC | $177.19 | 2019-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $174.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $118.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $116.65 | 2019-2022 | |
| Allergan, INC. | $114.67 | 2019-2020 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Caulfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.